Validation of Serum Pepsinogen II and Helicobacter Pylori Test in the Detection of Gastric Cancer in South Korea.

A clinical trial has been launched at Seoul National University Bundang Hospital in South Korea to validate the role of pepsinogens in gastric cancer screening. Serum pepsinogens are biomarkers for gastric cancer, particularly for atrophic gastritis and severe gastric inflammation. The study aims to collect sera and data from study subjects, measure pepsinogens and anti-H. pylori antibodies, and calculate optimal cutoff values for pepsinogens. The usefulness of pepsinogens in predicting the risk of gastric cancer will be validated through multivariate logistic regression and risk stratification. The trial is currently active and not recruiting, with an estimated completion date of December 31, 2025. [Extracted from the article]